Jonas Hallén

765 total citations
33 papers, 564 citations indexed

About

Jonas Hallén is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jonas Hallén has authored 33 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 12 papers in Surgery and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jonas Hallén's work include Acute Myocardial Infarction Research (13 papers), Cardiac Imaging and Diagnostics (7 papers) and Lipid metabolism and disorders (5 papers). Jonas Hallén is often cited by papers focused on Acute Myocardial Infarction Research (13 papers), Cardiac Imaging and Diagnostics (7 papers) and Lipid metabolism and disorders (5 papers). Jonas Hallén collaborates with scholars based in Norway, United States and Denmark. Jonas Hallén's co-authors include Dan Atar, Jesper K. Jensen, Allan S. Jaffe, Morten Wang Fagerland, Eva Swahn, Lena Jonasson, Peter Buser, Hans Olav Melberg, Sigrun Halvorsen and James L. Januzzi and has published in prestigious journals such as Circulation, Stroke and European Heart Journal.

In The Last Decade

Jonas Hallén

32 papers receiving 554 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonas Hallén Norway 15 369 127 127 75 65 33 564
Fang‐Yang Huang China 15 384 1.0× 140 1.1× 119 0.9× 107 1.4× 81 1.2× 61 644
Colin J. Petrie United Kingdom 13 424 1.1× 198 1.6× 136 1.1× 71 0.9× 32 0.5× 29 623
Toshiyuki Niki Japan 15 334 0.9× 149 1.2× 119 0.9× 65 0.9× 50 0.8× 28 588
Ivy Ku United States 12 431 1.2× 107 0.8× 151 1.2× 50 0.7× 134 2.1× 17 744
S Rajendran Australia 12 266 0.7× 95 0.7× 100 0.8× 33 0.4× 37 0.6× 34 505
Onur Sinan Deveci Türkiye 14 381 1.0× 117 0.9× 56 0.4× 52 0.7× 111 1.7× 53 608
Reiner Füth Germany 15 443 1.2× 98 0.8× 86 0.7× 100 1.3× 66 1.0× 24 642
Kuo‐Li Pan Taiwan 16 635 1.7× 182 1.4× 57 0.4× 130 1.7× 103 1.6× 74 928
Simona Giubilato Italy 13 265 0.7× 189 1.5× 106 0.8× 66 0.9× 117 1.8× 23 575
Maria Varoudi Greece 14 318 0.9× 87 0.7× 77 0.6× 96 1.3× 82 1.3× 23 655

Countries citing papers authored by Jonas Hallén

Since Specialization
Citations

This map shows the geographic impact of Jonas Hallén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Hallén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Hallén more than expected).

Fields of papers citing papers by Jonas Hallén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Hallén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Hallén. The network helps show where Jonas Hallén may publish in the future.

Co-authorship network of co-authors of Jonas Hallén

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Hallén. A scholar is included among the top collaborators of Jonas Hallén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Hallén. Jonas Hallén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Štorkánová, Hana, Thuong Trinh‐Minh, Hana Hulejová, et al.. (2023). S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin. Lara D. Veeken. 63(3). 817–825. 6 indexed citations
2.
Trinh‐Minh, Thuong, Andrea‐Hermina Györfi, Michal Tomčík, et al.. (2023). Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Arthritis & Rheumatology. 76(5). 783–795. 11 indexed citations
3.
Denton, Christopher P., Shiwen Xu, Kristina E N Clark, et al.. (2023). Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis. Annals of the Rheumatic Diseases. 82(9). 1205–1217. 6 indexed citations
4.
Melberg, Hans Olav, et al.. (2022). Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020. ESC Heart Failure. 10(1). 405–415. 18 indexed citations
5.
Melberg, Hans Olav, et al.. (2022). A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates. BMC Cardiovascular Disorders. 22(1). 88–88. 6 indexed citations
6.
Hallén, Jonas, et al.. (2020). Incidence, Prevalence, and Mortality of Heart Failure: A Nationwide Registry Study from 2013 to 2016. ESC Heart Failure. 7(4). 1917–1926. 21 indexed citations
7.
Maggioni, Aldo P., José López‐Sendón, Olav Wendelboe Nielsen, et al.. (2019). Efficacy and Safety of Serelaxin when Added to Standard of Care in Patients with Acute Heart Failure: Results from a PROBE Study, RELAX-AHF-EU. European Journal of Heart Failure. 21(3). 322–333. 19 indexed citations
8.
Kastelein, John J.P., Jonas Hallén, David A. Fraser, et al.. (2016). Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. Cardiology. 135(1). 3–12. 11 indexed citations
9.
Bays, Harold, Jonas Hallén, David A. Fraser, et al.. (2015). Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. Journal of clinical lipidology. 10(1). 181–191.e2. 24 indexed citations
10.
Hallén, Jonas, Mitchell W. Krucoff, Matthew T. Roe, et al.. (2014). Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. American Heart Journal. 169(2). 257–265.e1. 31 indexed citations
11.
Jarolı́m, Petr, et al.. (2013). Obstructive sleep apnea: no independent association to troponins. Sleep And Breathing. 18(2). 351–358. 5 indexed citations
12.
Kuliczkowski, Wiktor, Jonas Hallén, Mieczysław Woźniak, et al.. (2013). Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. Kardiologia Polska. 71(5). 453–463. 6 indexed citations
13.
Hallén, Jonas. (2012). Troponin for the Estimation of Infarct Size: What Have We Learned?. Cardiology. 121(3). 204–212. 75 indexed citations
14.
Hallén, Jonas, Jesper K. Jensen, Peter Buser, Allan S. Jaffe, & Dan Atar. (2011). Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction. Acute Cardiac Care. 13(1). 48–51. 6 indexed citations
15.
Ueland, Thor, Jonas Hallén, Dan Atar, et al.. (2011). Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis. 220(1). 244–249. 28 indexed citations
16.
17.
18.
Hallén, Jonas, Odd Erik Johansen, Kåre I. Birkeland, et al.. (2010). Determinants and prognostic implications of Cardiac Troponin T measured by a sensitive assay in Type 2 Diabetes Mellitus. Cardiovascular Diabetology. 9(1). 52–52. 35 indexed citations
19.
Hallén, Jonas, Peter Buser, Juerg Schwitter, et al.. (2009). Relation of Cardiac Troponin I Measurements at 24 and 48 Hours to Magnetic Resonance–Determined Infarct Size in Patients With ST-Elevation Myocardial Infarction. The American Journal of Cardiology. 104(11). 1472–1477. 47 indexed citations
20.
Karlsen, Trine, et al.. (2000). No difference in 3-day EPO response to 8, 12 or 16 hours/day of intermittant hypoxia. 251. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fang‐Yang Huang Breakdown of academic impact, for papers by Colin J. Petrie Breakdown of academic impact, for papers by Toshiyuki Niki Breakdown of academic impact, for papers by Ivy Ku Breakdown of academic impact, for papers by S Rajendran Breakdown of academic impact, for papers by Onur Sinan Deveci Breakdown of academic impact, for papers by Reiner Füth Breakdown of academic impact, for papers by Kuo‐Li Pan Breakdown of academic impact, for papers by Simona Giubilato Breakdown of academic impact, for papers by Maria Varoudi
Rankless by CCL
2026